Big Data, Bigger Insights

Menu Close LoginRegister Free
  • HOME
  • ABOUT
    • Citalytics Management
  • CITATION ANALYTICS APPLICATIONS
  • BUSINESS OPTIMIZATION SERVICES
  • BUSINESS INTELLIGENCE DASHBOARDS
  • REFMAP™ APPLICATION
    • REFMAP™ USER INTERFACE
    • REFMAP™ RAPID DEPLOYMENT
    • REFMAP™ CUSTOMIZATION
  • CITATION-DRIVEN MARKETING
    • BRAND MONITORING
    • CITATATION CONTENT MARKETING
    • refMAP™ APPLICATION
  • ACCOUNT
  • SUBSCRIPTION DETAILS
  • CONTACT US

Insights into New Brand Adoption Using Peer Review Mentions

March 11, 2016

SuperScript® has been a dominant brand in reverse transcription for 15 years now. Over the years, the mighty RT brand has churned out oodles of cDNA for use in a demanding range of RNA analysis techniques.

While enjoying the lion’s share of the RT market in 2002, Invitrogen decided to up the game a bit and introduce SuperScript® III.

We took a closer look at the citation trajectories of the reigning champ and it’s successor over the years. We had a few reasons for doing this:

  • We were interested in how long it would take a large firm like Invitrogen to “upgrade” its client base and how the adoption rate impacted citations.
  • We also wanted to see how RT-based applications grew in usage over the last 10-15 years. Since SuperScript® has owned such a large portion of many RT-based applications, we thought it would be a useful proxy for overall market growth.

A Look at the Numbers

As you can see, the SuperScript® brand didn’t really miss a beat during the SuperScript® II to III handoff. SuperScript® III citations continued along the same strong growth trajectory that SuperScript® II set in preceding years.

  • Impressively, SuperScript® III ran at a 156% CAGR in citations from 2003 to 2008
  • SuperScript® II flattened out during this period to a 7% CAGR
  • It took SuperScript® III over 7 years (mid-2010) to overcome SuperSript II’s citation footprint

Old Habits Transcribe Hard

Despite the marketing push and performance advantages of SuperScript® III, SuperScript® II seems to have maintained its cult following.

 

For the last 7 years, SuperScript® II citations have been relatively flat (1.5% CAGR), BUT they haven’t declined. Why is that?

We’re not insiders, so we don’t have a crystal ball into the situation, but we will have a few updates for you next month that look into a few regional trends and application associations that may shed some light on this. Stay tuned…

Recent Updates

  • CRISPR Applications Trending and Research Hotbeds
  • Example Research Profile Dashboard: Contact Mapping
  • Inside Contact Mapping Research: A Global View of Top Labs and Authors
  • Add Some Life and Sciences into your CRM
  • Navigating Dashboard Maps

Copyright 2023 Citalytics

Privacy Policy